GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2011

Active Biotech Receives €25M Up Front from Ipsen as Part of Cancer Deal

  • Ipsen is paying Active Biotech €25 million (about $36 million) up front and potentially another €150 million (roughly $217 million) in clinical, regulatory, and commercial milestones as part of a broad partnership agreement to co-develop and commercialize the latter’s anti-angiogenic cancer candidate, tasquinimod (ABR-215050). The drug is currently undergoing Phase III trials for the treatment of metastatic castrate-resistant prostate cancer.

    The deal with Ipsen covers continued development of tasquinimod for prostate cancer and potentially other oncology indications. Ipsen has exclusive rights to commercialize the drug worldwide except in North and South America and Japan, where Active retains all commercial and marketing rights. The firms will co-develop tasquinimod for castrate-resistant prostate cancer and any other other agreed cancer indications. Active will carry out and fund the ongoing Phase III clinical prostate cancer trial, and Ipsen will fund a supportive European study in prostate cancer patients. The firms will share the costs of developing tasquinimod for additional cancer indications.

    Ipsen says if tasquinimod is approved for the prostate cancer indication, the drug will complement its existing prostate cancer drug, Decapeptyl®/Trelstar®/Pamorelin® (triptorelin), which it markets under license from developer Debiopharm within the European Union (outside Sweden) and in certain other countries. Decapeptyl is approved in various markets in immediate-release and 1-, 3-, and 6-month sustained-release formulations.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »